Mylan snared in carcinogen scare with voluntary nizatidine recall

mylan
An FDA recall affects three lots of nizatidine sold between June 2017 and August 2018. (Mylan)

Following a global withdrawal of both generic statins and heartburn med Zantac, a spotlight has been trained on manufacturing that resulted in carcinogen-tainted drugs. Now, months after the Zantac scare, Mylan is the latest drugmaker forced to backtrack distribution of a popular generic. 

Mylan will recall three U.S. lots of nizatidine, USP, capsules after trace amounts of a probable carcinogen, N-Nitrosodimethylamine (NDMA), were found in the active pharmaceutical ingredient (API) in tested batches, the company said. The drug's API was produced by India-based drugmaker Solara Active Pharma Sciences.

Mylan's tainted batches of generic nizatidine, approved as a short-term treatment for duodenal ulcers, were distributed through June 2017 and August 2018, and no adverse events have been reported so far, the drugmaker said.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

The nizatidine recall comes months after positive NDMA testing triggered waves of global recalls and distribution halts for popular heartburn med Zantac (ranitidine). 

RELATED: Lab finds NDMA in Zantac can develop during storage

Suggested Articles

The U.K. became the first Western country to authorize a COVID vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.